Our mission is to transform the clinical management of patients with cancer by developing and delivering innovative molecular imaging technologies to address unmet clinical needs, and reliably inform diagnosis and treatment decisions.
Our team is made up of industry leaders and experts in the field of radiopharmaceutical development and commercialisation.
Blue Earth Diagnostics is backed by Syncona Limited, a leading FTSE250 healthcare company focused on investing in and building global leaders in life science.
Find out how this technique works
Find out about prostate cancer
Cellular mechanisms for amino acid transport
Our research focus
Who we are
See Our Latest Updates
See how you can join the team
Where we are going to be
− Results presented at ASTRO Annual Meeting evaluate clinical utility of 18F-fluciclovine PET/CT imaging in men with recurrent prostate cancer − BURLINGTON, Mass. and OXFORD, UK, September 16, 2019...
Read More ›BURLINGTON, Mass. and OXFORD, UK, September 10, 2019 – Blue Earth Diagnostics, a Bracco company focused on molecular imaging diagnostics, today announced upcoming presentations at the 2019 American Society...
Read More ›Oxford (UK), August 1st, 2019 – Bracco Imaging today announced that it has completed the acquisition of Blue Earth Diagnostics, a molecular imaging company based in Oxford, UK, from leading...
Read More ›‒ Blue Earth Diagnostics to become a subsidiary of Bracco Imaging; retains name and management team ‒ ‒ Acquisition driven by lead product Axumin® (fluciclovine F 18), a...
Read More ›